Skip to content

Source filing unavailable

Q3 2020 · —
Revenue—
Net Income-$6.07Mno prior Q3 2019 on fileN/M vs Q2 2020
EPS Diluted-$6.61no prior Q3 2019 on fileN/M vs Q2 2020
Operating Income-$6,053,000—
Operating Cash Flowderived-$4,921,000—
Free Cash Flowderived-$4,978,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q3 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR